A Phase 1 interventional study of Treprostinil Inhalation Powder in Pulmonary Arterial Hypertension, sponsored by United Therapeutics. Completed at 16 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-11-01.
Sponsored by United Therapeutics · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 44 studies testing treprostinil in Pulmonary Arterial Hypertension — 3 open to participants now, 5 under way, 2 of them phase 3. treprostinil · Pulmonary Arterial Hypertension.
Among the 44 studies testing treprostinil in Pulmonary Arterial Hypertension, this one is the 13th largest by enrollment, is one of 5 that started in 2019, is one of 9 in phase 1, and was the 37th registered.
701 studies on the registry are indexed under Pulmonary Arterial Hypertension; 142 are open to participants now.
Browse Pulmonary Arterial Hypertension studies →3 of the 44 studies testing treprostinil in Pulmonary Arterial Hypertension are open now, in 1 country. Recruiting first, the newest first:
Liquidia Technologies, Inc. · Sites in United States
Ages 18–80
University of Arizona · Sites in United States
Ages 18+
Shanghai Zhongshan Hospital
Ages 18–75
By country, each count listing its studies:
treprostinil: first FDA approval 2002 (REMODULIN), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →
Of the 90 Pulmonary Arterial Hypertension studies recruiting now, 51 (57%) set no upper age limit and 24 (27%) stop at 75 or younger; 18 take children under 18; 11 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
44 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 5 started in 2019.
This study's enrollment of 51 is above the median of 40 across 478 interventional studies indexed under Pulmonary Arterial Hypertension.
Median enrollment 32 across the 44 interventional studies. Of the 32 that completed or were terminated, 20 (63%) have results posted.
This tab as a report to print or save as PDF → With an account.
38 of 44 have an industry lead sponsor. The 10 most frequent:
United Therapeutics is the lead sponsor of 85 studies on the registry; 8 are open to participants now.
Of its 17 completed or terminated interventional studies of FDA-regulated products, 15 (88%) have results posted.
51 studies in Pulmonary Arterial Hypertension by United Therapeutics: 1 open now, 3 under way, 1 of them phase 3. Of 40 finished, 28 (70%) have results posted.
Among the 51 studies in Pulmonary Arterial Hypertension by United Therapeutics, this one is the 15th largest by enrollment of the 45 interventional ones that give a count, is one of 5 that started in 2019, is one of 8 in phase 1, and was the 48th registered.
United Therapeutics’s Pulmonary Arterial Hypertension studies by the year they started, since 2002.
1 of the studies testing treprostinil in Pulmonary Arterial Hypertension that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07759804Liquidia Technologies, Inc.A Study of Inhaled Treprostinil (LIQ861) in Adults With Pulmonary Arterial Hypertension Transitioning From Oral Selexipag | 2027-05 |
Add it to your calendar (.ics) → With an account.
Among the 44 studies testing treprostinil in Pulmonary Arterial Hypertension, from their registry updates:
Among United Therapeutics’s 51 in Pulmonary Arterial Hypertension:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This was a Phase 1b safety and tolerability single-sequence study in which PAH subjects on a stable regimen of Tyvaso switched to a corresponding dose of TreT.
United Therapeutics Corporation (UTC) developed a combination drug-device product comprised of a dry powder formulation of Treprostinil Inhalation Powder (TreT) and a small, portable, dry powder inhaler. In this Phase 1b safety and tolerability study, patients with PAH on a stable dose of Tyvaso (6 to 12 breaths 4 times daily [QID]) were evaluated after switching to a corresponding dose of TreT. Patients underwent PK assessments, safety assessments, a 6-Minute Walk Test (6MWT), and questionnaires for satisfaction/preference for inhaled devices and patient-reported PAH symptoms and impact. Following 3 weeks of treatment with TreT, patients were offered the opportunity to participate in the Optional Extension Phase until the drug/device became commercially available.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Women of were those who had experienced menarche and who had not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or were not (defined as amenorrhea for at least 12 consecutive months). WOCBP must have been nonpregnant (as confirmed by a urine pregnancy test at Screening prior to initiating study medication), nonlactating, and did 1 of the following:
Subject was diagnosed with PAH as defined by the following World Health Organization (WHO) Group 1 categories:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Each subject received a corresponding dose of TreT for 3 weeks during the Treatment Phase based on the subject's current stable Tyvaso dose.
Drug: Treprostinil Inhalation Powder
Treprostinil inhalation powder single-use cartridges containing either 32 or 48 micrograms of treprostinil per cartridge (QID)
Also known as: TreT
Change in 6-Minute Walk Distance (6MWD) From Baseline to Week 3
6MWD was evaluated at study entry and after 3 weeks of treatment with TreT.
Time frame: From Baseline to 3 weeks of treatment with TreT
Subject Satisfaction With and Preference for Inhaled Treprostinil Devices
Subject satisfaction with and preference for the inhaled treprostinil device was evaluated with the Preference Questionnaire for Inhaled Treprostinil Devices (PQ-ITD). The PQ-ITD is a questionnaire given to evaluate subject satisfaction with and preference for inhaled treprostinil devices. The questionnaire provides 12 different statements around inhaled device satisfaction and allows for 5 response options: strongly disagree, disagree, neutral, agree, and strongly agree.
Time frame: After 3 weeks of treatment with TreT (after switching from the Tyvaso Inhalation System)
Change in Patient-reported PAH Symptoms and Impact From Baseline to Week 3
Patient-reported PAH symptoms and impact were evaluated with the PAH Symptoms and Impact (PAH-SYMPACT) Questionnaire. The PAH-SYMPACT is a 23-item patient-reported outcome questionnaire that consists of 11 symptom items, 11 impact items, and 1 item on oxygen use. The symptom items are divided into cardiopulmonary and cardiovascular domains, and the impact items are divided into physical and emotional/cognitive domains. Symptom and impact domain scores (range 0 to 4) are calculated as the sum of the scores for the items included in the domain divided by the number of items in the domain. For all domains, a higher score indicates more severe symptoms/impacts.
Time frame: From Baseline to 3 weeks of treatment with TreT
Change in Patient-reported PAH Symptoms and Impact From Baseline to Week 11 (for Subjects Participating in the OEP)
Patient-reported PAH symptoms and impact were evaluated with the PAH Symptoms and Impact (PAH-SYMPACT) Questionnaire. The PAH-SYMPACT is a 23-item patient-reported outcome questionnaire that consists of 11 symptom items, 11 impact items, and 1 item on oxygen use. The symptom items are divided into cardiopulmonary and cardiovascular domains, and the impact items are divided into physical and emotional/cognitive domains. Symptom and impact domain scores (range 0 to 4) are calculated as the sum of the scores for the items included in the domain divided by the number of items in the domain. For all domains, a higher score indicates more severe symptoms/impacts.
Time frame: From Baseline to 11 weeks of treatment with TreT
| Milestone | Tyvaso to TreT |
|---|---|
| Started | 51 |
| Completed | 49 |
| Not completed | 2 |
| Withdrew: Adverse event | 2 |
| Milestone | Tyvaso to TreT |
|---|---|
| Started | 49 |
| Completed | 31 |
| Not completed | 18 |
| Withdrew: Death | 1 |
| Withdrew: Progressive disease | 5 |
| Withdrew: Adverse event | 7 |
| Withdrew: Lost to follow-up | 2 |
| Withdrew: Site closure | 2 |
| Withdrew: Pregnancy | 1 |
6MWD was evaluated at study entry and after 3 weeks of treatment with TreT.
| meters | Tyvaso to TreT |
|---|---|
| Change in 6-Minute Walk Distance (6MWD) From Baseline to Week 3 | 11.5 ± 32.9 |
Subject satisfaction with and preference for the inhaled treprostinil device was evaluated with the Preference Questionnaire for Inhaled Treprostinil Devices (PQ-ITD). The PQ-ITD is a questionnaire given to evaluate subject satisfaction with and preference for inhaled treprostinil devices. The questionnaire provides 12 different statements around inhaled device satisfaction and allows for 5 response options: strongly disagree, disagree, neutral, agree, and strongly agree.
| Participants | Tyvaso to TreT |
|---|---|
| Strongly Disagree | 0 |
| Disagree | 0 |
| Neutral | 1 |
| Agree | 5 |
| Strongly Agree | 40 |
Patient-reported PAH symptoms and impact were evaluated with the PAH Symptoms and Impact (PAH-SYMPACT) Questionnaire. The PAH-SYMPACT is a 23-item patient-reported outcome questionnaire that consists of 11 symptom items, 11 impact items, and 1 item on oxygen use. The symptom items are divided into cardiopulmonary and cardiovascular domains, and the impact items are divided into physical and emotional/cognitive domains. Symptom and impact domain scores (range 0 to 4) are calculated as the sum of the scores for the items included in the domain divided by the number of items in the domain. For all domains, a higher score indicates more severe symptoms/impacts.
| score on a scale | Tyvaso to TreT |
|---|---|
| Cardiopulmonary Symptoms Domain Score | -0.05 ± 0.27 |
| Cardiovascular Symptoms Domain Score | -0.06 ± 0.33 |
| Physical Impacts Domain Score | -0.14 ± 0.46 |
| Cognitive/Emotional Impacts Domain Score | -0.17 ± 0.40 |
Patient-reported PAH symptoms and impact were evaluated with the PAH Symptoms and Impact (PAH-SYMPACT) Questionnaire. The PAH-SYMPACT is a 23-item patient-reported outcome questionnaire that consists of 11 symptom items, 11 impact items, and 1 item on oxygen use. The symptom items are divided into cardiopulmonary and cardiovascular domains, and the impact items are divided into physical and emotional/cognitive domains. Symptom and impact domain scores (range 0 to 4) are calculated as the sum of the scores for the items included in the domain divided by the number of items in the domain. For all domains, a higher score indicates more severe symptoms/impacts.
| score on a scale | Tyvaso to TreT |
|---|---|
| Cardiopulmonary Symptoms Domain Score | -0.04 ± 0.36 |
| Cardiovascular Symptoms Domain Score | -0.05 ± 0.40 |
| Physical Impacts Domain Score | -0.20 ± 0.59 |
| Cognitive/Emotional Impacts Domain Score | -0.13 ± 0.51 |
Collected over All AEs were documented from the time of informed consent until the time screen failure was documented, until the subject either discontinued from the study, or the End of Study (EOS)/Early Termination (ET) assessments were completed, up to 201.1 weeks.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Tyvaso to TreT 32 mcg (Treatment Phase) | 0/2 (0%) | 0/2 (0%) | 0/2 (0%) |
| Tyvaso to TreT 48 mcg (Treatment Phase) | 0/27 (0%) | 1/27 (3.7%) | 17/27 (63%) |
| Tyvaso to TreT 64 mcg (Treatment Phase) | 0/22 (0%) | 1/22 (4.5%) | 14/22 (63.6%) |
| Tyvaso to TreT 32 mcg (Optional Extension Phase) | 0/2 (0%) | 1/2 (50%) | 2/2 (100%) |
| Tyvaso to TreT 48 mcg (Optional Extension Phase) | 0/26 (0%) | 12/26 (46.2%) | 25/26 (96.2%) |
| Tyvaso to TreT 64 mcg (Optional Extension Phase) | 1/21 (4.8%) | 12/21 (57.1%) | 20/21 (95.2%) |
| Event | Tyvaso to TreT 32 mcg (Treatment Phase) | Tyvaso to TreT 48 mcg (Treatment Phase) | Tyvaso to TreT 64 mcg (Treatment Phase) | Tyvaso to TreT 32 mcg (Optional Extension Phase) | Tyvaso to TreT 48 mcg (Optional Extension Phase) | Tyvaso to TreT 64 mcg (Optional Extension Phase) |
|---|---|---|---|---|---|---|
| Post procedural haemorrhageInjury, poisoning and procedural complications | 0/2 | 0/27 | 0/22 | 1/2 | 0/26 | 0/21 |
| Procedural painInjury, poisoning and procedural complications | 0/2 | 0/27 | 0/22 | 1/2 | 0/26 | 0/21 |
| HypotensionVascular disorders | 0/2 | 0/27 | 0/22 | 1/2 | 0/26 | 0/21 |
| Pulmonary hypertensionRespiratory, thoracic and mediastinal disorders | 0/2 | 0/27 | 0/22 | 0/2 | 3/26 | 0/21 |
| CellulitisInfections and infestations | 0/2 | 0/27 | 0/22 | 0/2 | 0/26 | 2/21 |
| Acute respiratory failureRespiratory, thoracic and mediastinal disorders | 0/2 | 0/27 | 0/22 | 0/2 | 0/26 | 2/21 |
| PneumoniaInfections and infestations | 0/2 | 0/27 | 0/22 | 0/2 | 2/26 | 0/21 |
| SyncopeNervous system disorders | 0/2 | 0/27 | 0/22 | 0/2 | 2/26 | 0/21 |
| Right ventricular failureCardiac disorders | 0/2 | 0/27 | 0/22 | 0/2 | 1/26 | 1/21 |
| Atrioventricular blockCardiac disorders | 0/2 | 0/27 | 0/22 | 0/2 | 0/26 | 1/21 |
| Event | Tyvaso to TreT 32 mcg (Treatment Phase) | Tyvaso to TreT 48 mcg (Treatment Phase) | Tyvaso to TreT 64 mcg (Treatment Phase) | Tyvaso to TreT 32 mcg (Optional Extension Phase) | Tyvaso to TreT 48 mcg (Optional Extension Phase) | Tyvaso to TreT 64 mcg (Optional Extension Phase) |
|---|---|---|---|---|---|---|
| HeadacheNervous system disorders | 0/2 | 4/27 | 4/22 | 2/2 | 6/26 | 4/21 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 0/2 | 2/27 | 2/22 | 2/2 | 10/26 | 4/21 |
| NauseaGastrointestinal disorders | 0/2 | 2/27 | 1/22 | 2/2 | 2/26 | 4/21 |
| CoughRespiratory, thoracic and mediastinal disorders | 0/2 | 11/27 | 7/22 | 1/2 | 4/26 | 4/21 |
| DiarrhoeaGastrointestinal disorders | 0/2 | 0/27 | 2/22 | 1/2 | 4/26 | 4/21 |
| AnaemiaBlood and lymphatic system disorders | 0/2 | 0/27 | 0/22 | 1/2 | 1/26 | 2/21 |
| VomitingGastrointestinal disorders | 0/2 | 0/27 | 1/22 | 1/2 | 4/26 | 1/21 |
| Oesophageal painGastrointestinal disorders | 0/2 | 0/27 | 0/22 | 1/2 | 0/26 | 0/21 |
| Chest painGeneral disorders | 0/2 | 1/27 | 0/22 | 1/2 | 2/26 | 0/21 |
| AstheniaGeneral disorders | 0/2 | 0/27 | 0/22 | 1/2 | 0/26 | 0/21 |
| Age, Continuous(years) | Tyvaso to TreT |
|---|---|
| Median | 57.0 (23 to 82) |
| Age, Customized(Participants) | Tyvaso to TreT |
|---|---|
| <65 years | 38 |
| ≥65 years | 13 |
| Sex: Female, Male(Participants) | Tyvaso to TreT |
|---|---|
| Female | 43 |
| Male | 8 |
| Ethnicity (NIH/OMB)(Participants) | Tyvaso to TreT |
|---|---|
| Hispanic or Latino | 4 |
| Not Hispanic or Latino | 47 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | Tyvaso to TreT |
|---|---|
| American Indian or Alaska Native | 1 |
| Asian | 1 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 9 |
| White | 40 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Region of Enrollment(participants) | Tyvaso to TreT |
|---|---|
| United States | 51 |
| Time Since PAH Diagnosis(years) | Tyvaso to TreT |
|---|---|
| Median | 7.820 (0.49 to 30.88) |
| Current PAH Diagnosis(Participants) | Tyvaso to TreT |
|---|---|
| Idiopathic/Familial | 29 |
| Associated with Unrepaired or Repaired Congenital Systemic-to-Pulmonary Shunts | 4 |
| Associated with Collagen Vascular Disease | 14 |
| Associated with HIV | 1 |
| Associated with Appetite Suppressant/Other Drug or Toxin Use | 3 |
2 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Sep 2019 to primary completion in Aug 2023, 47 months.
Results were first posted in Nov 2024, 1 year 2 months after primary completion.
Of 34 industry-sponsored phase 1 interventional studies under Pulmonary Arterial Hypertension, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 17. This study's 47 months is above that.
Counting every sponsor, half of 45 studies reached it within 9 months; a quarter within 2 and three quarters within 22.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Treprostinil
Pulmonary Arterial Hypertension →